Zhang Raymond J, Kim Tae Kon
Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN, USA.
Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.
Exp Mol Med. 2024 Nov;56(11):2348-2356. doi: 10.1038/s12276-024-01336-6. Epub 2024 Nov 1.
Over the past decade, V-domain immunoglobulin suppressor of T-cell activation (VISTA) has been established as a negative immune checkpoint molecule. Since the role of VISTA in inhibiting T-cell activation was described, studies have demonstrated other diverse regulatory functions in multiple immune cell populations. Furthermore, its relevance has been identified in human cancers. The role of VISTA in cancer immune evasion has been determined, but its mechanisms in the tumor microenvironment remain to be further elucidated. Understanding its contributions to cancer initiation, progression, and resistance to current treatments will be critical to its utility as a target for novel immunotherapies. Here, we summarize the current understanding of VISTA biology in cancer.
在过去十年中，T细胞激活的V结构域免疫球蛋白抑制因子（VISTA）已被确立为一种负性免疫检查点分子。自从VISTA在抑制T细胞激活方面的作用被描述以来，研究已证明它在多种免疫细胞群体中具有其他多种调节功能。此外，其在人类癌症中的相关性也已得到确认。VISTA在癌症免疫逃逸中的作用已被确定，但其在肿瘤微环境中的机制仍有待进一步阐明。了解其对癌症起始、进展以及对当前治疗耐药性的影响，对于将其作为新型免疫疗法的靶点的应用至关重要。在此，我们总结了目前对VISTA在癌症中的生物学特性的理解。
